Study of chemical stability of antivirally active 5-azacytosine acyclic nucleoside phosphonates using NMR spectroscopy

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 14, 2008, Pages 6778-6782

  Dračínský, Martin ^a   Krečmerová, Marcela ^a   Holý, Antonín ^a  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

5 Azacytosine; NMR spectroscopy; Reaction kinetics; Triazine ring opening

Indexed keywords

1 [2 (PHOSPHONOMETHOXY)ETHYL] 5 AZACYTOSINE; 1 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 5 AZACYTOSINE; 1 [[2 HYDROXY 2 OXIDO 1,4,2 DIOXAPHOSPHINAN 5 YL]METHYL] 5 AZACYTOSINE; 2 [2 (PHOSPHONOMETHOXY)ETHYL]CARBAMOYLGUANIDINE; 2 [2,3 DIHYDROXYPROPYL]CARBAMOYLGUANIDINE; 2 [3 FORMYLOXY 2 (PHOSPHONOMETHOXY)PROPYL]CARBAMOYLGUANIDINE; 2 {[2 HYDROXY 2 OXIDO 1,4,2 DIOXAPHOSPHINAN 5 YL]METHYL}CARBAMOYLGUANIDINE; 2,3 DIHYDROXYPROPYL 5 AZACYTOSINE; 5 AZACYTOSINE ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVE; ANTIVIRUS AGENT; CARBAMOYLGUANIDINE DERIVATIVE; CYTOSINE DERIVATIVE; GUANIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DECOMPOSITION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INHIBITION; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANTIVIRAL AGENTS; CYTOSINE; DRUG STABILITY; GUANIDINES; HYDROLYSIS; MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOSIDES; PHOSPHONIC ACIDS;

EID: 47349115510     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.05.058     Document Type: Article

References (24)

1. Holý A. Curr. Pharm. Des. 9 (2003) 2567-2592
2. Krečmerová M., Holý A., Pískala A., Masojídková M., Balzarini J., Andrei G., Snoeck R., Naesens L., Neyts J., and De Clercq E. J. Med. Chem. 50 (2007) 1069-1077
3. Pískala A., and Šorm F. Collect. Czech. Chem. Commun. 29 (1964) 2060-2076
4. Pliml J., and Šorm F. Collect. Czech. Chem. Commun. 29 (1964) 2576-2578
5. Kuykendall J.R. Ann. Pharmacother. 39 (2005) 1700-1708
6. Momparler R.L., Bouffard D.Y., Momparler L.F., Dionne J., Belanger K., and Ayoub J. Anticancer Drugs 8 (1997) 358-368
7. Thibault A., Figg W.D., Bergan R.C., Lush R.M., Myers C.E., Tompkins A., Reed E., and Samid D. Tumori 84 (1998) 87-89
8. Jones P.A. Cell 40 (1985) 485-486
9. Momparler R.L., Cote S., and Eliopoulos N. Leukemia 11 (1997) S1-S6
10. Momparler R.L., Cote S., and Eliopoulos N. Leukemia 11 (1997) 175-180
11. Bender C.M., Pao M.M., and Jones P.A. Cancer Res. 58 (1998) 95-101
12. Jones P.A., and Baylin S.B. Nat. Rev. Genet. 3 (2002) 415-428
13. Krečmerová M., Holý A., Pohl R., Masojídková M., Andrei G., Naesens L., Neyts J., Balzarini J., De Clercq E., and Snoeck R. J. Med. Chem. 50 (2007) 5765-5772
14. Duraffour S., Snoeck R., Krečmerová M., van Den Oord J., De Vos R., Holý A., Crance J.-M., Garin D., De Clercq E., and Andrei G. Antimicrob. Agents Chemother. 51 (2007) 4410-4419
15. Lebeau I., Andrei G., Krečmerová M., De Clercq E., Holý A., and Snoeck R. Antimicrob. Agents Chemother. 51 (2007) 2268-2273
16. Andrei G., Krečmerová M., Holý A., Naesens L., Neyts J., Balzarini J., De Clercq E., and Snoeck R. Antiviral Res. 74 (2007) A33-A34
17. Pithová P., Pískala A., Pitha J., and Šorm F. Collect. Czech. Chem. Commun. 30 (1965) 2801-2811
18. Beisler J.A. J. Med. Chem. 21 (1978) 204-208
19. Lin T.-S., Momparler R.L., and Rivard G.E. J. Pharm. Sci. 70 (1981) 1228-1232
20. Liu Z., Marcucci G., Byrd J.C., Grever M., Xiao J., and Chan K.K. Rapid Commun. Mass Spectrom. 20 (2006) 1117-1126
21. Frisch M.J., et al. Gaussian 03 (2004), Gaussian, Inc., Wallingford, CT
22. Lee C., Yang W., and Parr R.G. Phys. Rev. B Condens. Mater. Phys. 37 (1988) 785
23. Becke A.D. J. Chem. Phys. 98 (1993) 5648
24. Mennucci B., Cancès E., and Tomasi J. J. Phys. Chem. B 101 (1997) 10506